Gilead Sciences, Inc. (GILD)
Pre-market:
| Previous close | 67.34 |
| Open | 67.41 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1300 |
| Day's range | 67.22 - 68.69 |
| 52-week range | 61.39 - 74.12 |
| Volume | |
| Avg. volume | 7,784,737 |
| Market cap | 84.382B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 11.51 |
| EPS (TTM) | 5.84 |
| Earnings date | 02 Feb 2022 - 07 Feb 2022 |
| Forward dividend & yield | 2.84 (3.93%) |
| Ex-dividend date | 14 Dec 2021 |
| 1y target est | 76.88 |
- Zacks
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
- Bloomberg
Former J&J Scientist Stoffels to Lead Galapagos Revival Bid
(Bloomberg) -- More than 20 years ago, Paul Stoffels helped form Belgian biotechnology company Galapagos NV. Now he’s headed back to lead an effort to revive it.Most Read from BloombergApple to Rival Square by Turning iPhones Into Payment TerminalsStocks Drop in Roller-Coaster Ride for Wall Street: Markets WrapPowell Backs March Liftoff, Won’t Rule Out Hike Every MeetingA Nor’easter Approaching New York Risks Becoming a Bomb CycloneJeremy Grantham Has an Even Scarier Prediction Than His Crash Ca
- Zacks
Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
